N. Bodick

2.5k total citations · 1 hit paper
42 papers, 1.9k citations indexed

About

N. Bodick is a scholar working on Rheumatology, Pharmacology and Molecular Biology. According to data from OpenAlex, N. Bodick has authored 42 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Rheumatology, 15 papers in Pharmacology and 14 papers in Molecular Biology. Recurrent topics in N. Bodick's work include Osteoarthritis Treatment and Mechanisms (17 papers), Inflammatory mediators and NSAID effects (10 papers) and Tendon Structure and Treatment (5 papers). N. Bodick is often cited by papers focused on Osteoarthritis Treatment and Mechanisms (17 papers), Inflammatory mediators and NSAID effects (10 papers) and Tendon Structure and Treatment (5 papers). N. Bodick collaborates with scholars based in United States, United Kingdom and Canada. N. Bodick's co-authors include Walter Offen, Andrew Satlin, H E Shannon, Joelle Lufkin, Serge Gauthier, Philip G. Conaghan, Frank P. Bymaster, Cyrus Levinthal, K. Rasmussen and Gary D. Tollefson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, American Journal of Psychiatry and Journal of Bone and Joint Surgery.

In The Last Decade

N. Bodick

42 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease

1997 528 citations N. Bodick, Walter Offen et al. Archives of Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N. Bodick United States	22	730	582	508	412	278	42	1.9k
Claude Desnuelle France	37	2.1k 2.9×	709 1.2×	180 0.4×	148 0.4×	126 0.5×	140	3.8k
Fran Borovečki Croatia	24	1.6k 2.3×	882 1.5×	144 0.3×	194 0.5×	181 0.7×	98	2.9k
Andrea Calvo Italy	46	1.3k 1.8×	722 1.2×	573 1.1×	336 0.8×	266 1.0×	195	7.1k
Matthew J. Schwei United States	16	655 0.9×	661 1.1×	105 0.2×	355 0.9×	393 1.4×	16	3.1k
Klaus Wirth Germany	37	985 1.3×	478 0.8×	100 0.2×	269 0.7×	229 0.8×	154	5.2k
Vivian E. Drory Israel	26	428 0.6×	286 0.5×	77 0.2×	136 0.3×	135 0.5×	100	2.2k
Bruce Quinn United States	25	604 0.8×	586 1.0×	148 0.3×	297 0.7×	334 1.2×	44	2.2k
Young Seok Park South Korea	22	302 0.4×	338 0.6×	159 0.3×	70 0.2×	208 0.7×	116	1.6k
Takekazu Kubo Japan	26	798 1.1×	869 1.5×	196 0.4×	216 0.5×	39 0.1×	54	2.3k
Leontino Battistin Italy	23	399 0.5×	379 0.7×	180 0.4×	88 0.2×	153 0.6×	53	2.0k

Countries citing papers authored by N. Bodick

Since Specialization

Citations

This map shows the geographic impact of N. Bodick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Bodick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Bodick more than expected).

Fields of papers citing papers by N. Bodick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Bodick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Bodick. The network helps show where N. Bodick may publish in the future.

Co-authorship network of co-authors of N. Bodick

This figure shows the co-authorship network connecting the top 25 collaborators of N. Bodick. A scholar is included among the top collaborators of N. Bodick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Bodick. N. Bodick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boyce, Rogely, et al.. (2021). Efficacy and Safety of FX201, a Novel Intra-Articular IL-1Ra Gene Therapy for Osteoarthritis Treatment, in a Rat Model. Human Gene Therapy. 33(9-10). 541–549. 14 indexed citations

Bowes, M.A., Katherine Kacena, Oras Alabas, et al.. (2020). Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative. Annals of the Rheumatic Diseases. 80(4). 502–508. 80 indexed citations

Frank, E., et al.. (2019). Dose-dependent chondroprotective effects of triamcinolone acetonide on inflamed and injured cartilage using an in vitro model. Osteoarthritis and Cartilage. 27. S176–S176. 7 indexed citations

Bodick, N., Toni Williamson, Vibeke Strand, et al.. (2018). Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs. Rheumatology and Therapy. 5(2). 475–498. 11 indexed citations

Mehra, P., et al.. (2017). Synovial and systemic pharmacokinetics of triamcinolone acetonide following intra-articular injection of an extended release formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis. Osteoarthritis and Cartilage. 25. S431–S431. 3 indexed citations

Conaghan, Philip G., Vibeke Strand, David J. Hunter, et al.. (2017). An intra-articular, extended release formulation of triamcinolone (FX006) affords clinically relevant improvements in pain and function of knee osteoarthritis: post-hoc pooled analyses of 3 randomized controlled trials. Osteoarthritis and Cartilage. 25. S432–S433. 3 indexed citations

Kraus, Virginia B., Philip G. Conaghan, P. Mehra, et al.. (2017). Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). Osteoarthritis and Cartilage. 26(1). 34–42. 107 indexed citations

Williamson, Toni, Antje‐Christine Walz, Ruth Lightfoot-Dunn, et al.. (2017). Systemic and local effects following intra-articular injection of FX006, an extended release, PLGA microsphere formulation of triamcinolone acetonide: results from two nonclinical toxicity studies in dogs. Osteoarthritis and Cartilage. 25. S431–S432. 5 indexed citations

Conaghan, Philip G., Stanley Cohen, Joanne M. Jordan, et al.. (2016). Sustained and profound analgesic benefits in people with osteoarthritis of the knee using FX006, an intra-articular extended-release formulation of triamcinolone acetonide: Results from a double-blind, randomized, parallel-group, dose-ranging study. Osteoarthritis and Cartilage. 24. S49–S50. 3 indexed citations

10.

Bodick, N., et al.. (2015). Prolonged joint residency of triamcinolone acetonide after an intra-articular injection of FX006, a sustained release formulation for the treatment of osteoarthritis. Osteoarthritis and Cartilage. 23. A360–A361. 4 indexed citations

11.

Bodick, N., Joelle Lufkin, Anjali S. Kumar, et al.. (2015). An Intra-Articular, Extended-Release Formulation of Triamcinolone Acetonide Prolongs and Amplifies Analgesic Effect in Patients with Osteoarthritis of the Knee. Journal of Bone and Joint Surgery. 97(11). 877–888. 98 indexed citations

12.

Kumar, Anjali S., et al.. (2014). A single intra-articular dose of Fx006, an extended-release formulation of triamcinolone acetonide, has a similar effect on cartilage in healthy dogs as the commonly used kenalog-40® suspension. Osteoarthritis and Cartilage. 22. S463–S464. 2 indexed citations

13.

Bodick, N., Joelle Lufkin, Anjali S. Kumar, et al.. (2014). Safety and efficacy of FX006 in patients with osteoarthritis of the knee. Osteoarthritis and Cartilage. 22. S376–S377. 2 indexed citations

14.

Bodick, N., et al.. (2013). FX006 prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis. Osteoarthritis and Cartilage. 21. S144–S145. 14 indexed citations

15.

Kumar, Anjali S., et al.. (2012). Sustained efficacy of intra-articular FX006 in a rat model of osteoarthritis. Osteoarthritis and Cartilage. 20. S289–S289. 5 indexed citations

16.

Bonabeau, Eric, N. Bodick, & Robert W. Armstrong. (2008). Un enfoque más racional para el desarrollo de nuevos productos. Harvard business review. 86(3). 92–98. 1 indexed citations

17.

Veroff, Amy E., et al.. (1998). Efficacy of Xanomeline in Alzheimer Disease: Cognitive Improvement Measured Using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Disease & Associated Disorders. 12(4). 304–312. 47 indexed citations

18.

Gauthier, Serge, N. Bodick, Howard Feldman, et al.. (1997). Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.. PubMed. 11 Suppl 3. 6–7. 22 indexed citations

19.

Bodick, N., Walter Offen, Allan I. Levey, et al.. (1997). Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease. Archives of Neurology. 54(4). 465–473. 528 indexed citations breakdown →

20.

Stevens, John K., et al.. (1983). Serial reconstruction of microtubular arrays within dendrites of the cat retinal ganglion cell: The cytoskeleton of a vertebrate dendrite. Brain Research. 259(2). 193–206. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact